"I don't see Prop. 61 as being a constructive answer to drug pricing issues," said Richard Evans, a health care analyst for SSR, an investment research firm.
Big pharma spending big dollars to defeat California measure →
Evans said, "You've got to be sure you have security. That would be my only concern. You used to be able to drive across it when I was young."
New access sought to old dam →